Catalent, Inc. announced that David McErlane has been named Group President of Catalent?s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza?s Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca.

He holds a bachelor?s degree in electronic systems engineering from Glasgow Caledonian University. Mr. McErlane will lead all of Catalent?s Biologics businesses and global service offerings ? including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services.